Anti-VEGF Campaign Member Survey

In 2018, ARVO members were asked to suggest topics for ARVO’s next advocacy campaign. Six topic proposals were received, with multiple submissions on anti-vascular endothelial growth factor (VEGF) therapy. These submissions were reviewed by the Advocacy and Outreach Committee (AOC) which approved/recommended anti-VEGF for the campaign. During its spring 2019 meeting the ARVO Board of Trustees (BoT) approved the topic of anti-VEGF therapy.

ARVO staff, with support from an Advisory Committee, are developing a campaign aimed at educating policymakers about the importance of the investment made using federal research dollars to develop anti-VEGF. In part by using health care cost databases, we will conduct an analysis to demonstrate a return-on-investment (ROI).

Question Title

* 1. Are you familiar with the basic research regarding the role of VEGF in ocular neovascularization?

Yes

If you answered "Yes" to Question 1, please respond to the questions below.
If you answered "No" to Question 1, please submit the survey without responding to the questions below.

Question Title

* 2. How knowledgeable are you about this research?

I am extremely familiar with anti-VEGF research

I am reasonably familiar with anti-VEGF research

I am only vaguely familiar with anti-VEGF research

Question Title

* 3. In your opinion, how critical was this research to the eventual development of current anti-VEGF therapies that are being used to treat wet AMD, diabetic macular edema, etc. (e.g. Lucentis, Eylea, Avastin)

Not at all

It had some influence

It had a good deal of influence

The drugs would not have been developed without the basic research

Anti-VEGF Campaign Member Survey

Question Title

* 1. Are you familiar with the basic research regarding the role of VEGF in ocular neovascularization?

Question Title

* 2. How knowledgeable are you about this research?

Question Title

* 3. In your opinion, how critical was this research to the eventual development of current anti-VEGF therapies that are being used to treat wet AMD, diabetic macular edema, etc. (e.g. Lucentis, Eylea, Avastin)

Question Title

* 4. Did you receive NIH funding to conduct research directly on or tangential to anti-VEGF?

Question Title

* 5. If yes, through which Institute?

Question Title

* 6. What do you think policymakers should know about this research?

Question Title

* 7. If comfortable, please leave your name and email address